Esketamine for the Treatment of Rett Syndrome

Inclusion Criteria: * Classic/typical RTT * Causing mutation in MECP2 gene * Stable pattern of seizures, or has had no seizures at least 8 weeks Exclusion Criteria: * Use of other drugs that interact with Esketamine: thyroxine, meglumine diatrizoate, aminophylline, diazepam or midazolam, drugs for antihypertension or central nervous depressants, halogenated general anesthetics (e.g., halothane), tubocurarine, atracurium * Condition with hypertension, high cerebrospinal fluid pressure, and high intraocular pressure * Unstable systemic illness other than Rett syndrome: current clinically significant cardiovascular, endocrine (such as hypo- or hyperthyroidism, type 1 diabetes, or uncontrolled type 2 diabetes), renal, hepatic, respiratory, or gastrointestinal disease (such as celiac disease or inflammatory bowel disease), or major surgery planned during the study * Clinically important variations in medication use